Deutsche Bank Starts BioMarin Pharmaceutical Inc. (BMRN) at Buy
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Deutsche Bank initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Buy rating and a price target of $106. Analyst Andrew Peters sees a clear path to profitability.
"We view BioMarin as a core holding in mid-cap biotech and see significant upside potential over the next 12mos driven by both continued commercial execution and clinical progress. With 3 new products expected to launch over the next 3-5 years, as well as an earlier-stage pipeline that includes additional potential blockbuster programs (with near-term read-outs), we believe the company is set up well for outperformance. Further, given the current environment and push for external sources of growth, we view BioMarin as a top strategic target in biotech, but view the potential number of suitors are far smaller than many of its smaller-cap peers," said the analyst.
Shares of BioMarin Pharmaceutical Inc. closed at $80.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Shopify (SHOP) at Perform
- Dougherty & Co Starts Quality Systems (QSII) at Neutral
- Jefferies Cuts Price Target on Kroger (KR) to $30 Following 3Q and Guidance
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesDeutsche Bank
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!